Another breakthrough development from Glenmark Pharmaceuticals that the company has completed pre-clinical evaluation for its novel bi-specific antibody GBR 1302 and filed the Phase I trial application with German regulatory authorities.
Glenmark Pharmaceuticals SA, has submitted a clinical trial application for GBR 1302 to the Paul-Ehrlich Institute in Germany. GBR 1302 has the potential to be used in the treatment of a broad array of cancers, including breast cancer, and the company expects to obtain approval for the initiation of clinical studies during this financial year.
GBR 1302 material for Phase I clinical trials with manufactured at the Glenmark GMP production unit in Switzerland. A bi-specific monocloncal antibody is an artificial protein that is composed of fragments of two different monocloncal antibodies and consequently binds two different types of antigens.
